Avance Clinical Wins 2024 Frost & Sullivan Award for Global Biotech CRO Excellence
ADELAIDE, Australia and WAKE FOREST, N.C., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, a leading global CRO specializing in clinical trials for the biotech sector, has won the prestigious 2024 Frost & Sullivan Best Practices Customer Value Leadership Award for Global Biotech CRO Excellence.
Avance Clinical CEO Yvonne Lungershausen thanked Frost & Sullivan for the global award and said they recognized the entire Avance Clinical team across the globe working together to accelerate clients’ drug development.
“Our agile, customer centric and integrated approach to progressing clinical research for our biotech clients is clearly resonating in an industry that too often has a one size fits all model,” she said.
Frost & Sullivan is a globally recognized authority in identifying and honoring companies that demonstrate excellence leadership, innovation and growth.
According to Frost & Sullivan, “These companies consolidate their leadership positions by innovating and creating new products, solutions, and services that meet ever-evolving customer needs. By strategically broadening their product portfolios, leading companies advance the overall market. Driving innovation and growth is a difficult task made even harder by the strategic imperatives forcing change today, such as disruptive technologies, value chain compression, industry convergence, and new business models”.
“In this context, Avance Clinical’s recognition signifies an even greater accomplishment.”
The award report noted that Avance Clinical, headquartered in Adelaide, Australia, is now a leading global CRO facilitating top-tier clinical trials with globally recognized data for biotech firms worldwide.
“With an exclusive focus on the biotech sector, the company has significant deep clinical research experience across 250+ therapeutic indications to provide customized services catering to biotech R&D’s dynamic needs,” said the report.
The report also highlighted that Avance Clinical has particularly robust expertise in Cell & Gene Therapies, Central Nervous System (CNS), Dermatology, Endocrinology, Infectious Diseases, Oncology, Ophthalmology, Rare Disease & Orphan Drug, and Respiratory & Allergy indications. Overall, the company’s world-class team exceeding 330 clinical and regulatory specialists delivers high-quality clinical trials in Australia, New Zealand, Asia, and North America for international biotechs.
Frost & Sullivan also noted that: “The company’s flat organizational structure provides customers with direct access to leadership teams, facilitating continual collaboration throughout their drug development journeys”.
The report said that the company’s unique approach to project management, where each project receives individual oversight, has resulted in high customer satisfaction rates and impressive client retention.
Frost & Sullivan said Avance Clinical offered a strong business case for biotechs. Especially considering their research “found over 50% of biotechs engage with more than one CRO throughout their clinical programs, leading to a less streamlined approach that increases project costs, delays, and knowledge/data transfer challenges”.
“Unlike larger multinational CROs, this intimate approach enables Avance Clinical to understand customer challenges closely, empowering it to deliver flexible solutions and hands-on guidance that optimally position it to match the fast-paced nature of biotech R&D. As a result, the company’s agility and responsiveness make it the ideal partner for small to mid-sized biotech companies, addressing a crucial need that competitors often struggle to fulfill,” said Unmesh Lal, Global Research Director.
The award report also noted:
- In-House Regulatory Affairs: One of Avance Clinical’s most compelling value propositions is its in-house regulatory team that seamlessly integrates into its biotech clients’ clinical and project delivery operations to minimize delays and costly errors (decreasing the trial startup timeline by up to 50% and reducing costs by up to 30%).
- Site Partnerships: Avance Clinical continues to invest strategically in building strong relationships with clinical sites capable of conducting Phase I to IV clinical trials, forming an expansive network of over 2,000 high-quality, trusted clinical trial sites across Australia, New Zealand, the US, Canada, and Europe.
- Advanced Technology: In addition to facilitating a company-wide application of industry-standard technologies, Avance Clinical’s Technology and Innovations team continually identifies and reviews the latest technology solutions, including machine learning and artificial intelligence (AI) applications, to support global systems integrations.
- A Global Approach: The company’s unique GlobalReady model supports biotechs from their early pre-clinical stage through to later phases across the globe, leveraging the right site relationships to deliver access to the optimal patient populations. The GlobalReady program enables seamless transition and coordination between regions, allowing biotechs to utilize its expertise across various markets.
- Expedited Recruitment: Avance Clinical’s strong network facilitates quick feasibility evaluations and rapid progression through start-up activities, allowing for expedited patient recruitment. This efficiency, in turn, translates to shorter overall timelines for the company’s biotech clients, ensuring faster and more effective clinical trials, including accelerated study start-up durations of five to six weeks.
Sama Suwal, the Best Practice Research Analyst at Frost & Sullivan said Avance Clinical’s global network is a clear advantage for its clients, “Avance Clinical’s globalized strategy extends its presence into new geographies through organic expansions and partnerships to better serve its biotech customers’ growing global needs…the company continues to spread its footprint across the United States (US) and Asia while strengthening its CRO partnerships through Europe”.
Find out more:
• Learn about the GlobalReady model
• For more information about the benefits of running your next study with Avance Clinical contact us
• Request a Proposal here
About Avance Clinical | Request a Proposal
Avance Clinical is the largest premium full-service Australian, Asian and North American CRO delivering quality clinical trials with globally accepted data for international biotechs. The company’s clients are biotechs completing Phase I to Phase III of their drug development program that requires fast, agile, and adaptive solution-oriented clinical research services.
Frost & Sullivan Awards
Avance Clinical, a Frost & Sullivan Asia-Pacific CRO Market Leadership Award recipient for the past four years, has been providing CRO services in the region for more than three decades.
Pre-clinical through to mid to late phase
Avance Clinical offers pre-clinical consulting and regulatory services with their experienced ClinicReady team right from pre-clinical consultancy through to Phase III clinical services leveraging significant Australian Government incentive rebates of up to 43.5% and rapid start-up regulatory processes.
With experience across more than 250 indications, the CRO can deliver world-class results and high-quality internationally accepted data for TGA, FDA and EMA review.
Technology
Avance Clinical uses state-of-the-art technology and gold standard systems across all functional areas to provide clients with the most effective processes. Medidata, Oracle, TrialHub, Certinia, Salesforce, Zelta and Medrio are just some of the technology partners.
www.avancecro.com
Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson
- Smith+Nephew partners with HOPCo to provide AI-powered analytics and solutions to ASC customers
- 鱼跃凯立特2024院内经销商年会顺利举办
- 全民参与·创新驱动·绿色未来,阿拉善SEE气候周在京开幕
- 义乌市友久贸易有限公司四川分公司时尚潮品店给消费市场注入一股全新的活力
- “词曲中国2023十大男女高音词曲作品评选”在京顺利结束
- 科技守护长久陪伴,火星人集成灶交上母亲节完美答卷
- 东呈重仓加码,华东酒店市场重构进行时
- 广西国际创新生物科技生态产业基地奠基仪式在南宁举行
- 松山棉店武汉首店盛大开业:东方美学与天然材质的完美邂逅
- CITE2024首日,造物数科InZ应龙启幕,展示电子电路智慧云工厂新范式
- 陨石产业国际标准制定委员会在平湖正式成立
- 宝丰金石:石墨制品在真空炉中的应用有哪些
- 石墨在汽车行业中的应用:轻量化、高性能的新选择
- 河南爱视力药业与南阳海之达共绘绿色新篇:每月 1 日“大地美容”公益行动持续升温
- 暑期圆梦旅行,上汽奥迪Q6伴你达成愿望清单
- 2024年度义乌购十大经营户评选活动启动
- noco-noco and Neogen Forge Strategic Partnership to Unleash X-SEPA™ Technology in India's Burge
- 衡泰信即将再次亮相全球最大高尔夫展会:美国奥兰多PGA SHOW
- 华邦科技集团成员“港湾家族办公室”隆重开幕 成立家办启新篇 力促多元化发展
- 亮相佛罗伦萨时装周,足力健老人鞋演绎舒适之美
- 共建全民健康 达因药业获评自我药疗教育工作先进会员单位
- 欧舒丹私有化要约“极具吸引力”,公司与股东共赢
- Seoul Semiconductor为2024款Genesis GV80前大灯提供WICOP,引领前大灯潮流
- 盟非之家丨2024科创供应链数字经济高峰论坛成功举行
- 凡泰极客亮相 2024 AWS 出海全球化论坛,为企业数字化出海赋能
- 舒华运动研究院将携手IWF国际健身展 举办全球健身趋势论坛
- 北京泰和养老:以高质量服务托举起老年人的幸福生活
- 生物质反烧炉:环保解决方案,实现可持续发展。(圣昊朗道)
- Instagram,ins自动引流软件,一键解锁引流涨粉新境界!
- Wipro与Nokia联合推出5G专用无线解决方案,加速企业数字化转型
推荐
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 中国减排方案比西方更有优势 如今,人为造成的全球变暖是每个人都关注的问 资讯
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 王自如被强制执行3383万 据中国执行信息公开网消息,近期,王自如新增一 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 看新东方创始人俞敏洪如何回应董宇辉新号分流的? (来源:中国证券报) 东方甄选净利润大幅下滑 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯